Evidence map›Paper›PMID 34169405›Full record

ReviewNeurotoxicity research2021

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review.

Sedigheh Eskandari, Soraya Sajadimajd, Loghman Alaei, Zhaleh Soheilikhah, Hossein Derakhshankhah, Gholamreza Bahrami

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Innovative approaches for the treatment of stroke: a recent update.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Cells · 2023
    Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sedigheh EskandariPharmaceutical Science Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Soraya SajadimajdDepartment of Biology, Faculty of Science, Razi University, Kermanshah, Iran. sajadi.s62@gmail.com.ORCID https://orcid.org/0000-0002-9188-1426
Loghman AlaeiDepartment of Biology and Biotechnology, Faculty of Sciences, University of Kurdistan, Sanandaj, Iran.
Zhaleh SoheilikhahPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hossein DerakhshankhahPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Derakhshankhah.hossein@gmail.com.ORCID https://orcid.org/0000-0002-0951-2729
Gholamreza BahramiMedical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases such as stroke and Alzheimer's disease (AD) are two inter-related disorders that affect the neurons in the brain and central nervous system. Alzheimer's is a disease by undefined origin and causes. Stroke and its most common type, ischemic stroke (IS), occurs due to the blockade of cerebral blood vessels. As an important feature, both of disorders are associated with irreversible damages to the brain and nervous system. In this regard, finding common signaling pathways and the same molecular origin between these two diseases may be a promising way for their solution. On the basis of literature appraisal, the most common signaling cascades implicated in the pathogenesis of AD and stroke including notch, autophagy, inflammatory, and insulin signaling pathways were reviewed. Furthermore, current therapeutic strategies including natural and synthetic pharmaceuticals aiming modulation of respective signaling factors were scrutinized to ameliorate neural deficits in AD and stroke. Taken together, digging deeper in the common connections and signal targeting can be greatly helpful in understanding and unified treating of these disorders.

Indexed as

Alzheimer DiseaseAngiotensin II Type 1 Receptor BlockersAnimalsAutophagyBrainDrug Delivery SystemsHumansInsulinSignal TransductionStrokeTumor Necrosis Factor InhibitorsAngiotensin II Type 1 Receptor BlockersInsulinTumor Necrosis Factor InhibitorsAlzheimer’s diseaseNeurodegenerative disordersSignaling pathwaysStrokeTherapeutic strategy

Identifiers

PMID34169405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.